Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | CNR1 | P21554 | 4/20 | 0.62 |
| ▸ | CNR2 | P34972 | 4/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3772656 | 0.90 | ALDH1A1 (0.74) | ALDH1A1CNR1CNR2KDM4EMAPT | |
| SCHEMBL494586 | 0.89 | ALDH1A1 (0.59) | ALDH1A1CNR1CNR2KDM4EMAPT | |
| SCHEMBL493687 | 0.85 | L3MBTL1 (0.51) | ALDH1A1CNR1CNR2KDM4EMAPT | |
| SCHEMBL3074551 | 0.85 | ALDH1A1 (0.66) | ALDH1A1CNR1CNR2KDM4EMAPT | |
| SCHEMBL4563297 | 0.83 | ALDH1A1 (0.52) | ALDH1A1CNR1CNR2KDM4EMAPT | |
| SCHEMBL4254441 | 0.83 | ALDH1A1 (0.52) | ALDH1A1CNR1CNR2KDM4EMAPT | |
| SCHEMBL493492 | 0.83 | TDP1 (0.52) | ALDH1A1CNR1CNR2KDM4ENPSR1 | |
| SCHEMBL5136398 | 0.82 | KMT2A (0.52) | ALDH1A1CNR1CNR2KDM4EMAPT | |
| SCHEMBL3069120 | 0.80 | L3MBTL3 (0.67) | ALDH1A1CNR1CNR2KDM4EMAPT | |
| SCHEMBL493703 | 0.80 | ALDH1A1 (0.46) | ALDH1A1CNR1CNR2L3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2024354-B1 | 1- [ (4- [BENZOYL (METHYL) AMINO]-3- (PHENYL) BUTYL]AZETIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS 1 | ALBIREO AB (SE) | 2011-09-21 | — | — | EP | claimed |
| EP-2024354-A1 | 1- [ (4- [BENZOYL (METHYL) AMINO]-3- (PHENYL) BUTYL]AZETIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS 1 | Albireo AB (SE) | 2009-02-18 | — | — | EP | claimed |
| WO-2007136324-A1 | 1- [ (4- [BENZOYL (METHYL) AMINO] -3- (PHENYL) BUTYL] AZETIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS 1 | ALBIREO AB (SE) | 2007-11-29 | — | — | WO | claimed |
| US-20070270398-A1 | New Compounds III | ALBIREO AB (SE) | 2007-11-22 | — | — | US | claimed |
| US-8106208-B2 | Benzamide compounds that act as NK receptor antagonists | ALBIREO AB (SE) | 2012-01-31 | — | — | US | disclosed |
| EP-2024354-B1 | 1- [ (4- [BENZOYL (METHYL) AMINO]-3- (PHENYL) BUTYL]AZETIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS 1 | ALBIREO AB (SE) | 2011-09-21 | — | — | EP | disclosed |
| EP-2024354-A1 | 1- [ (4- [BENZOYL (METHYL) AMINO]-3- (PHENYL) BUTYL]AZETIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS 1 | Albireo AB (SE) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007136324-A1 | 1- [ (4- [BENZOYL (METHYL) AMINO] -3- (PHENYL) BUTYL] AZETIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS 1 | ALBIREO AB (SE) | 2007-11-29 | — | — | WO | disclosed |
| US-20070270398-A1 | New Compounds III | ALBIREO AB (SE) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270398-A1 | New Compounds III | CYP11B2, CYP11B1, SDHA | ALDH1A1 561/4885CNR1 1044/4885CNR2 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.